Comparison Study of PTHrP and PTH to Treat Osteoporosis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and
two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators
want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal
women with osteoporosis stimulates bone formation to the same or greater degree than PTH
(1-34) but with less bone resorption.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)
Treatments:
Hormones Parathyroid Hormone Parathyroid Hormone-Related Protein Teriparatide